Annolyse
BriefingsCompaniesScreenerInsightsPrinciplesCompareChatWatchlist

Explore

  • Briefings
  • Companies
  • Screener
  • Insights
  • Compare

Resources

  • Search
  • Methodology

© 2026 Annolyse.

ChartsAnalysisChatData
  1. Charts
  2. Valuation
  3. Analysis
  4. Chat
  5. Data
  6. Sources
←Back to briefings
Third Age Health Services (TAH) / FY23

Revenue nearly doubled but PBT fell 56% as costs outpaced growth

Effective tax rate jumped from 24.9% to 43.5%, deepening the NPAT decline to 67% while operating cash flow held essentially flat at $1.1m.

Healthcare / Primary healthcare

TAH revenue trajectory

Revenue context before the current result.

↗
Loading chart...
FY23 was $11.5m, versus $5.9m in FY22.

TAH operating cash flow

Operating cash flow across covered periods.

↗
Loading chart...
FY23 was $1.1m, versus $1.1m in FY22.

TAH working-capital movement

Operating working-capital absorption or release by reporting period.

↗
Loading chart...
FY23 was $0.8m, versus -$380.5m in HY23.

TAH NPAT trajectory

Statutory profit after tax across covered periods.

↗
Loading chart...
FY23 was $0.4m, versus $1.2m in FY22.

Market context

Valuation

A close-dated read on what the market price implies next to the latest verified filing inputs. Unavailable metrics stay visible when the absence is useful context.

Prices as at close, 12 June 2026

Price and market cap

The latest close and share count context for the market price.

Market cap

$45.9m

i

End-of-day close multiplied by current shares on issue.

Profitability multiples

How the market price compares with recent earnings and cash-flow inputs.

P/E

16.39x

i

Recent market cap compared with trailing earnings.

EPS

0.28

i

Recent filing-derived earnings per share.

PEG

0.76x

i

P/E compared with recent earnings growth.

EV/EBITDA

7.67x

i

Enterprise value compared with recent EBITDA.

P/FCF

11.63x

i

Market cap compared with recent free cash flow.

P/B

8.33x

i

Market value compared with latest reported equity.

Income and fund shape

Yield and fund-style valuation where the company shape supports it.

Dividend yield

3.5%

i

Trailing dividends compared with the latest close.

Total return

Not available

i

Available once dividend and adjustment data are verified.

Release date
26 May 2023
Published
28 April 2026
Ask about this result
Sections⌄
  1. Charts
  2. Valuation
  3. Analysis
  4. Chat
  5. Data
  6. Sources

Key metrics

Numbers worth scanning first

FY23 vs FY22

Revenue

$11.5m

+94.4% ↑ vs $5.9m

EBITDA

$1.6m

— vs —

Net profit after tax

$0.4m

-66.7% ↓ vs $1.2m

Net cash inflow from operating activities

$1.1m

+3.9% ↑ vs $1m

Full-year dividend per share

5.0c

-41.3% ↓ vs 8.6c

Profit before tax

$0.7m

-56.2% ↓ vs $1.6m

Cash and cash equivalents

$1.4m

+20.6% ↑ vs $1.1m

Total assets

$10m

+106.7% ↑ vs $4.9m

What changed

Revenue nearly doubled to $11.5m (+94.4%), yet profit before tax fell 56.2% to $0.7m and NPAT dropped 66.7% to $0.4m

The effective tax rate climbed from 24.9% to 43.5%, which means NPAT fell roughly 10 percentage points further than PBT, so PBT is the cleaner read on operating performance. Group EBITDA was $1.6m (no comparable prior figure disclosed).

Operating cash flow was essentially unchanged at $1.1m (+3.9%) despite revenue doubling. The balance sheet expanded sharply: total assets more than doubled to $10.0m, gross borrowings of $2.3m now sit on the balance sheet against nil a year ago, and equity slipped 5.6% to $2.5m. Trade debtors more than tripled to $1.1m, lifting receivable days from 21.2 to 35.6. The release attributes $3.7m of revenue to recent acquisitions and $1.9m to organic growth (FY22 organic: $0.1m).

What matters

Profit fell while revenue nearly doubled

Capital raise adds balance-sheet context, with NZ$2m capital raised, but borrowings and gearing are the direct leverage evidence.

PBT declined 56.2% on a 94.4% revenue uplift, indicating the cost base expanded faster than the top line. This is the central tension in the result: management has built scale, but FY23 absorbed direct and indirect integration and consolidation costs in the first half that the second half did not fully recover. Until margin recovery is demonstrated in a clean period, the operating economics of the larger group remain unproven.

Tax distortion widened the headline decline. The effective tax rate moved from 24.9% to 43.5%, a roughly 18.6pp step-up. No driver is disclosed in the supplied material, so NPAT understates the underlying operating result and full reconciliation is outstanding. Investors should weight PBT over NPAT when judging FY23 performance.

Working capital absorbed cash that revenue would otherwise have produced. Operating cash flow rose just 3.9% while revenue rose 94.4%, because receivable days lengthened from 21.2 to 35.6 and operating working capital expanded by roughly $0.8m. This matters because it raises the cash cost of growth and, if it persists, will constrain dividend and debt-service capacity at the new larger scale.

Expectations

No forward revenue, earnings, or dividend guidance is supplied in the released material, and no quantified targets are disclosed

The half-year split is therefore the only available shape reference: 1H23 contained roughly 39.9% of full-year revenue and 44.6% of full-year EBITDA, but 74% of reported NPAT, so 2H reported NPAT was materially weaker than 1H ($0.1m vs $0.3m). Management points to underlying second-half improvement and a $150k annualised cost reduction; that framing is not visible in reported NPAT. The release does not provide enough to judge whether FY24 will inherit a recovered or still-compressed margin from the second half, which is the key open shape question.

Quality of result

The result is mixed quality

On the positive side, capex remains very light at $0.1m (0.5% of revenue), so free cash flow pre-lease of roughly $1.0m closely tracks operating cash flow. Payout ratio versus pre-lease FCF is suppressed because the denominator basis is not suitable for numeric display. FCF/NPAT of 234.9% reflects the depressed NPAT denominator rather than unusually strong cash generation; OCF/EBITDA at 69.4% is more representative and suggests meaningful, but not exceptional, conversion.

Less durable signals dominate the read. Operating cash flow barely moved despite revenue doubling, because $0.8m of incremental working capital tied up the growth. The dividend at 122.4% of NPAT exceeds reported earnings cover, leaving FCF, not earnings, as the funding source for distributions. ROE fell from 43.5% to 17.2%, partly reflecting a larger asset base now carrying $2.3m of debt against $2.5m of equity. The combination of higher leverage, longer receivable days, and a tax line that has not been reconciled in the supplied disclosures means the FY23 print should not yet be treated as a clean baseline for forward earnings power.

Unresolved

Open questions

Why did the effective tax rate jump from 24.9% to 43.5%, and is the FY23 rate the right run-rate for FY24?
What is the underlying group margin once first-half integration costs are excluded, and is the 2H exit margin sustainable?
How quickly will receivable days revert toward the FY22 level of 21.2, and what is driving the extension?
Is a dividend representing 122.4% of FY23 NPAT sustainable if NPAT does not recover, given the FCF payout ratio is suppressed pending a suitable denominator basis?
What further integration spend, if any, is expected in FY24 before the larger group runs at a steady-state cost base?

This briefing cannot assess management's specific cost-reduction initiatives, segment-level margin trajectories, or FY24 trading momentum because the supplied material contains no forward financial guidance or post-period trading commentary.

Chat

Ask about TAH FY23

Ask follow-up questions about Third Age Health Services's FY23 result.

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Ask about TAH FY23

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Sign in to chat

Sign in to ask questions about Third Age Health Services's FY23 result.

Why did the effective tax rate jump from 24.9% to 43.5%, and is the FY23 rate the right run-rate for FY24?Why does "Profit fell while revenue nearly doubled" matter?How strong was the cash and earnings quality in FY23?What should I watch next for TAH after FY23?

Checking account...

Data appendix

Show segment detail

Open to load segment breakdown.

Show analytical metrics

Open to load analytical metrics.

Show key metrics table

Open to load key metrics.

Sources

Current period

Chair and CEO Update

FY23 / results release↗

Preliminary Results

FY23 / financial report↗

Presentation Highlights

FY23 / results presentation↗

Results Announcement

FY23 / results announcement↗

Prior comparable period

Release of Annual Report 2022

FY22 / results announcement↗

Release of Annual Report 2022

FY22 / results release↗

TAH Annual Report 2022

FY22 / financial report↗

Interim context

Interim Report

HY23 / financial report↗

Interim Results Announcement

HY23 / results release↗

TAH company filing

HY23 / results announcement↗

Related insights

Cross-company views selected from the metrics in this briefing.

Earnings quality and statutory distortions

PBT and NPAT growth diverged by 10.5pp, with a distortion flag in the result.

→

Cash conversion quality

This result converted 69.4% of EBITDA to operating cash flow.

→

Dividend coverage and payout pressure

Company-disclosed payout ratio is 75.0% on a NPAT basis, with NPAT payout at 122.4%.

→

Revenue growth context

Revenue growth was 94.4% for this reporting period.

→
This briefing is based on available company filings and standard Annolyse calculations. It is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.

Get notified when TAH publishes next

Get the next Third Age Health Services briefing and related NZX reporting-season updates by email.